血管紧张素转化酶 2 在 COVID-19 诱导的肺损伤中的作用。
The role of angiotensin-converting enzyme 2 in COVID-19 induced lung injury.
机构信息
Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Department of Biochemistry, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran.
出版信息
Acta Biomed. 2020 Nov 10;91(4):e2020142. doi: 10.23750/abm.v91i4.10159.
Abstract
The novel coronavirus disease (COVID-19) has affected people around the world both physically and psychologically. As result, developing coronavirus-specific vaccine and/or therapeutics is now a top priority for public health agencies. Since our findings about COVID-19 are relatively new, the current knowledge about the molecular mechanism involved in pathogenicity and virulence of the novel coronavirus is not advanced. Understanding angiotensin-converting enzyme 2 (ACE2), the receptor for the coronavirus, is significantly important. To better illustrate the role of ACE2 in the severity of COVID-19 and the impact of currently used drugs on this receptor, this paper briefly reviews newly published articles in this regard.
摘要
新型冠状病毒病（COVID-19）在身体和心理两方面影响着全世界的人们。因此，开发针对冠状病毒的疫苗和/或疗法现在是公共卫生机构的首要任务。由于我们对 COVID-19 的了解相对较新，目前关于新型冠状病毒致病性和毒力涉及的分子机制的知识还不够先进。了解血管紧张素转换酶 2（ACE2），即冠状病毒的受体，具有重要意义。为了更好地说明 ACE2 在 COVID-19 严重程度中的作用，以及目前使用的药物对该受体的影响，本文简要回顾了这方面新发表的文章。
相似文献
1
The role of angiotensin-converting enzyme 2 in COVID-19 induced lung injury.血管紧张素转化酶 2 在 COVID-19 诱导的肺损伤中的作用。
Acta Biomed. 2020 Nov 10;91(4):e2020142. doi: 10.23750/abm.v91i4.10159.
2
Linking ACE2 and angiotensin II to pulmonary immunovascular dysregulation in SARS-CoV-2 infection.将 ACE2 和血管紧张素 II 与 SARS-CoV-2 感染中的肺免疫血管失调联系起来。
Int J Infect Dis. 2020 Dec;101:42-45. doi: 10.1016/j.ijid.2020.09.041. Epub 2020 Sep 17.
3
Angiotensin-Converting Enzyme Gene Polymorphism and Severe Lung Injury in Patients with Coronavirus Disease 2019.血管紧张素转化酶基因多态性与 2019 年冠状病毒病患者的严重肺损伤。
Am J Pathol. 2020 Oct;190(10):2013-2017. doi: 10.1016/j.ajpath.2020.07.009. Epub 2020 Jul 29.
4
Interaction Between Coronavirus S-Protein and Human ACE2: Hints for Exploring Efficient Therapeutic Targets to Treat COVID-19.冠状病毒S蛋白与人ACE2之间的相互作用：探索治疗COVID-19有效治疗靶点的线索
Angiology. 2021 Feb;72(2):122-130. doi: 10.1177/0003319720952284. Epub 2020 Aug 30.
5
Angiotensin-Converting Enzyme 2 (ACE2) in the Pathogenesis of ARDS in COVID-19.血管紧张素转换酶 2（ACE2）在 COVID-19 所致急性呼吸窘迫综合征发病机制中的作用。
Front Immunol. 2021 Dec 22;12:732690. doi: 10.3389/fimmu.2021.732690. eCollection 2021.
6
Angiotensin-converting enzyme 2 (ACE2), SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19).血管紧张素转化酶 2（ACE2）、严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）与 2019 冠状病毒病（COVID-19）的病理生理学。
J Pathol. 2020 Jul;251(3):228-248. doi: 10.1002/path.5471. Epub 2020 Jun 10.
7
Angiotensin-converting enzyme 2: a double-edged sword in COVID-19 patients with an increased risk of heart failure.血管紧张素转换酶 2：COVID-19 患者心力衰竭风险增加的双刃剑。
Heart Fail Rev. 2021 Mar;26(2):371-380. doi: 10.1007/s10741-020-10016-2.
8
Could SARS-CoV-2-induced lung injury be attenuated by vitamin D?维生素 D 能否减轻 SARS-CoV-2 诱导的肺损伤？
Int J Infect Dis. 2021 Jan;102:196-202. doi: 10.1016/j.ijid.2020.10.059. Epub 2020 Oct 28.
9
Organ-protective effect of angiotensin-converting enzyme 2 and its effect on the prognosis of COVID-19.血管紧张素转换酶 2 的器官保护作用及其对 COVID-19 预后的影响。
J Med Virol. 2020 Jul;92(7):726-730. doi: 10.1002/jmv.25785. Epub 2020 Apr 5.
10
Coronavirus Disease 2019 and Hypertension: The Role of Angiotensin-Converting Enzyme 2 and the Renin-Angiotensin System.2019冠状病毒病与高血压：血管紧张素转换酶2及肾素-血管紧张素系统的作用
Adv Chronic Kidney Dis. 2020 Sep;27(5):404-411. doi: 10.1053/j.ackd.2020.07.002. Epub 2020 Jul 4.
引用本文的文献
1
Mental Healthcare in Pediatrics During the COVID-19 Pandemic: A Call for International Public Health Action.儿科心理健康保健在 COVID-19 大流行期间：呼吁国际公共卫生行动。
Adv Exp Med Biol. 2024;1458:19-34. doi: 10.1007/978-3-031-61943-4_2.
2
Spike protein receptor-binding domains from SARS-CoV-2 variants of interest bind human ACE2 more tightly than the prototype spike protein.刺突蛋白受体结合域来自于引起关注的 SARS-CoV-2 变体，比原型刺突蛋白更紧密地结合人类 ACE2。
Biochem Biophys Res Commun. 2023 Jan 22;641:61-66. doi: 10.1016/j.bbrc.2022.12.011. Epub 2022 Dec 5.
3
Altered immunoemotional regulatory system in COVID-19: From the origins to opportunities.COVID-19 中改变的免疫情绪调节系统：从起源到机遇。
J Neuroimmunol. 2021 Jul 15;356:577578. doi: 10.1016/j.jneuroim.2021.577578. Epub 2021 Apr 16.
4
A systematic review of pregnant women with COVID-19 and their neonates.对 COVID-19 孕妇及其新生儿的系统评价。
Arch Gynecol Obstet. 2021 Jul;304(1):5-38. doi: 10.1007/s00404-021-06049-z. Epub 2021 Apr 2.
本文引用的文献
1
SARS-CoV-2-A Tough Opponent for the Immune System.SARS-CoV-2-免疫系统的强大对手。
Arch Med Res. 2020 Aug;51(6):589-592. doi: 10.1016/j.arcmed.2020.05.020. Epub 2020 May 30.
2
The immune system and COVID-19: Friend or foe?免疫系统与 COVID-19：敌是友？
Life Sci. 2020 Sep 1;256:117900. doi: 10.1016/j.lfs.2020.117900. Epub 2020 Jun 2.
3
COVID-19: Transmission, prevention, and potential therapeutic opportunities.新型冠状病毒肺炎：传播、预防和潜在治疗机会。
Clin Chim Acta. 2020 Sep;508:254-266. doi: 10.1016/j.cca.2020.05.044. Epub 2020 May 29.
4
Towards treatment planning of COVID-19: Rationale and hypothesis for the use of multiple immunosuppressive agents: Anti-antibodies, immunoglobulins, and corticosteroids.针对 COVID-19 的治疗规划：使用多种免疫抑制剂的原理和假设：抗抗体、免疫球蛋白和皮质类固醇。
Int Immunopharmacol. 2020 Jul;84:106560. doi: 10.1016/j.intimp.2020.106560. Epub 2020 May 8.
5
Cardiovascular Risks in Patients with COVID-19: Potential Mechanisms and Areas of Uncertainty.COVID-19 患者的心血管风险：潜在机制和不确定领域。
Curr Cardiol Rep. 2020 Apr 29;22(5):34. doi: 10.1007/s11886-020-01293-2.
6
Interactions of coronaviruses with ACE2, angiotensin II, and RAS inhibitors-lessons from available evidence and insights into COVID-19.冠状病毒与 ACE2、血管紧张素 II 和 RAS 抑制剂的相互作用——来自现有证据的教训和对 COVID-19 的深入了解。
Hypertens Res. 2020 Jul;43(7):648-654. doi: 10.1038/s41440-020-0455-8. Epub 2020 Apr 27.
7
Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis.危重症和死亡 COVID-19 病例的风险因素：系统文献回顾和荟萃分析。
J Infect. 2020 Aug;81(2):e16-e25. doi: 10.1016/j.jinf.2020.04.021. Epub 2020 Apr 23.
8
Zinc and respiratory tract infections: Perspectives for COVID‑19 (Review).锌与呼吸道感染：COVID-19 的展望（综述）。
Int J Mol Med. 2020 Jul;46(1):17-26. doi: 10.3892/ijmm.2020.4575. Epub 2020 Apr 14.
9
Nafamostat Mesylate Blocks Activation of SARS-CoV-2: New Treatment Option for COVID-19.甲磺酸那法莫司他可阻断新型冠状病毒激活：新冠肺炎的新治疗选择。
Antimicrob Agents Chemother. 2020 May 21;64(6). doi: 10.1128/AAC.00754-20.
10
ACE-2 expression in the small airway epithelia of smokers and COPD patients: implications for COVID-19.吸烟者和 COPD 患者小气道上皮中的 ACE-2 表达：对 COVID-19 的影响。
Eur Respir J. 2020 May 14;55(5). doi: 10.1183/13993003.00688-2020. Print 2020 May.
Zotero 插件